Targeted protein degradation (TPD) is a promising therapeutic approach, with molecular degraders of extracellular proteins (MoDEs) as a key technology. MoDEs are hetero-bifunctional compounds that combine a TriGalNAc ligand targeting the ASGPR receptor with peptide ligands for specific proteins.

Using our AI-based drug discovery platform, EDDY, we perform large-scale virtual screening to identify high-affinity small molecules for both ASGPR and target proteins. This approach enables the design of MoDEs with improved oral availability and optimized pharmacokinetics/pharmacodynamics (PK/PD).

Our proof-of-concept goal is to refine and apply EDDY to develop next-generation MoDEs targeting ASGPR and pathogenic proteins.